Home › Trial NCT06420089
CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)
- Trial IDNCT06420089
- StatusRecruiting
- PhasePhase 1
- Study typeInterventional
- SponsorVittoria Biotherapeutics
- Enrollment30
- Start date2024-10-04
- ConditionsT Cell Non-Hodgkin Lymphoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.